Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Lawn, Stephen D ^a,b   Campbell, Lucy ^a,c   Kaplan, Richard ^a   Little, Francesca ^a   Morrow, Carl ^a   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RIFAMPICIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT REFERRAL; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; RISK FACTOR; SOUTH AFRICA; THERAPY DELAY; TREATMENT PLANNING; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; HEALTH SERVICES RESEARCH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METHODOLOGY; TIME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HEALTH SERVICES RESEARCH; HIV INFECTIONS; HUMANS; MALE; SOUTH AFRICA; TIME FACTORS; TUBERCULOSIS;

EID: 80053345802     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-258     Document Type: Article

References (25)

1. World Health Organization Global tuberculosis control. A short update to the 2009 report. 2009, WHO, Geneva, Accessed on 01.03.10, World Health Organization., http://www.who.int/tb/publications/global_report/2009/update/tbu_9.pdf
2. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 2009, 13:6-16.
3. Lawn SD, Kranzer K, Wood R. Antiretroviral Therapy for Control of the HIV-associated Tuberculosis Epidemic in Resource-Limited Settings. Clin Chest Med 2009, 30:685-699. 10.1016/j.ccm.2009.08.010, 2887494, 19925961.
4. Lawn SD, Torok ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis 2011, 24:34-42. 10.1097/QCO.0b013e3283420f76, 21150593.
5. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 43:42-46. 10.1097/01.qai.0000230521.86964.86, 16885778.
6. Velasco M, Castilla V, Sanz J, Gaspar G, Condes E, Barros C, Cervero M, Torres R, Guijarro C. Effect of Simultaneous Use of Highly Active Antiretroviral Therapy on Survival of HIV Patients With Tuberculosis. J Acquir Immune Defic Syndr 2009, 50:148-152. 10.1097/QAI.0b013e31819367e7, 19131895.
7. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697-706. 10.1056/NEJMoa0905848, 3076221, 20181971.
8. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents.Recommendations for a publc health approach (2010 revision). World Health Organization, Geneva, Accessed on 19.12.10, World Health Organization., http://www.who.int/hiv/pub/arv/adult/en/index.html
9. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, et al. Significant enhancement in survival with early (2 weeks) vs late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. 2010, Abstracts of the XVIII International AIDS Conference, Vienna, Austria, International AIDS Society. Abstract THLBB1..
10. Havlir D, Ive P, Kendall M, Luetkemeyer A, Swindells S, Kumwenda J, Qasba S, Hogg E, Anderson J, Sanne I, et al. International randomised trial of immediate vs early ART in HIV+ patients treated for TB: ACTG5221 STRIDE study. Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections 2011, Boston, MA, USA, Abstract #38;.
11. Abdool Karim S, Naidoo K, Padayatchi N, Grobler A, Baxter C, Sengiah S, El-Sadr W, Friedland G, Abdool Karim Q. Optimal timing of ART durign TB therapy; findings of the SAPIT trial. Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections 2011, Boston, MA, USA, Abstract #39LB.
12. National Department of Health SA National antiretrovial treatment guidelines, first edition. 2004, National Department of Health SA.
13. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006, 20:1605-1612. 10.1097/01.aids.0000238406.93249.cd, 16868441.
14. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007, 21:335-341. 10.1097/QAD.0b013e328011efac, 17255740.
15. Lawn SD, Fraenzel A, Kranzer K, Caldwell J, Bekker LG, Wood R. Provider initiated HIV testing increases access of patients with HIV-associated tuberculosis to antiretroviral therapy. S Afr Med J 2011, 101:258-262.
16. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010, 24:1323-1328.
17. World Health Organisation Scaling up Antiretroviral Therapy in Resource-limited Settings. Guidelines for a Public Health Approach 2003, Geneva: World Health Organisation, 2003 Revision., World Health Organisation.
18. World Health Organisation Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. Accessed on 17.07.11, World Health Organisation., http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf
19. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006, 43:770-776. 10.1086/507095, 16912954.
20. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
21. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005, 19:2141-2148. 10.1097/01.aids.0000194802.89540.e1, 16284464.
22. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J, Lu Z, Losina E, Walensky RP, Freedberg KA. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009, 51:135-139. 10.1097/QAI.0b013e3181a44ef2, 2747614, 19504725.
23. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22:1897-1908. 10.1097/QAD.0b013e32830007cd, 18784453.
24. Lawn SD, Campbell L, Kaplan R, Boulle A, Cornell M, Kerschberger B, Morrow C, Little F, Egger M, Wood R. Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South Africa. J Acquir Immune Defic Syndr 2011, 57:136-140. 10.1097/QAI.0b013e3182199ee9, 21436714.
25. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010, 10:489-498. 10.1016/S1473-3099(10)70078-5, 20610331.